Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 5,414,409 shares of IMTX stock, worth $27.7 Million. This represents 1.47% of its overall portfolio holdings.
Number of Shares
5,414,409
Previous 3,904,862
38.66%
Holding current value
$27.7 Million
Previous $44.6 Million
13.6%
% of portfolio
1.47%
Previous 1.61%
Shares
7 transactions
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.6MShares$54.2 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA10.4MShares$53.2 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$47.9 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$37.2 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$33.4 Million0.76% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $390M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...